1 / 35

The therapy of respiratory infections

The therapy of respiratory infections. Dr Heidi Orth Dept Medical Microbiology. Upper respiratory infections (URTI). Pharyngitis/Tonsillitis Causes. Resp viruses – most common Bacteria – 5-30% Group A -hemolytic streptococci (GABHS) ( S. pyogenes)

ember
Download Presentation

The therapy of respiratory infections

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The therapy of respiratory infections Dr Heidi Orth Dept Medical Microbiology

  2. Upper respiratory infections (URTI)

  3. Pharyngitis/TonsillitisCauses • Resp viruses – most common • Bacteria – 5-30% • Group A -hemolytic streptococci (GABHS) (S. pyogenes) • Non-infective causes – allergy; exposure to irritants

  4. Rx Streptococcal pharyngitis/tonsillitisto prevent complications • Penicillin • Pen V x 10 days • Benzatine penicillin (IMI injection) Alternatives: • Amoxycillin x 10 days • Better absorption • Skin rash may follow if EBV pharyngitis – may diagnose incorrectly as pen allergy • Only indicated if pos culture with GABHS

  5. Short course therapy (3-5 days) • 5 days: e.g. Amoxicillin/clavulanate; Clarithromycin; oral cephalosporins • 3 days: • Azitromycin

  6. Acute otitis media (AOM) • Viruses • Bacterial causes: • Streptococcus pneumoniae • Haemophilus influenzae (non-typeable) • Moraxella catarrhalis • Indications for antibiotics: • Recurrent AOM • Immunocompromised pt • <2yrs • Structural ENT abnormalities • Fever>38C or pain>48hrs • Daycare attendees

  7. Selected cases - observation on symptomatic treatment only • Observe for 48-72hrs without antibacterial Rx in selected cases • >2yrs with non-severe AOM or where diagnosis uncertain • Requires good follow up and presence of adult that can monitor the child • Give Paracetamol or Ibuprofen for pain • Decongestants – use in AOM controversial, topically x 3 days rather than orally

  8. Rx of AOM in children • High dose Amoxicillin 90mg/kg/day in 2-3 divided doses 5-7days – drug of choice • 7-10 days therapy for <2yrs; recurrent/chronic AOM and complicated cases • If fever>72hr on appropriate therapy, refer to ENT specialist for tympanocentesis and cultures

  9. Alternatives • Amox/clav – also effective against B-lactamase producing H. influenzae and M catarrhalis – if no response on amox alone; first line for severe disease (T39C, severe otalgia) • Oral cephalosporins: cefuroxime and cefpodoxime - not effective against high level penicillin resistant pneumococci • Parenteral cephalosporins (Ceftriaxone) – for severe cases e.g. mastoiditis or where no response on high doses amox/clav; or if vomiting and not tolerating oralmeds • Macrolides e.g. azithromycin/clarithromycin– if allergic to penicillin

  10. AOM with otorrhoea in patients with tympanostomy tubes (TT) • Culture of otorrhoea fluid in patients with TT often yield bacteria such as Pseudomonas and Staphylococcus aureus. • These pathogens can be treated with topical ciprofloxacin drops

  11. Prevention of AOM • 7-valent pneumococcal vaccine • Recently introduced in S.A. (Prevenar) • Also now in public sector available • End 2008 launched in Eastern Cape • 2009 – other provinces

  12. Acute bacterial sinusitis(ABS) • Predisposing factors: • Viral URTI • Allergy, trauma or tooth infection may lead to inflammation of nasal and para-nasal sinus membranes • Bacterial causes: • Streptococcus pneumoniae • Haemophilus influenzae • Moraxella catarrhalis Less common • Other streptococci; anaerobes and Staphylococcus aureus • Chlamydophila pneumoniae – chronic sinusitis • Fungi – immunocompromised patients

  13. Important factors • Recent antibiotics - select for resistant organisms • Duration of Rx: 10 days • New agents: moxifloxacin (fluoroquinolone) 5-7 days • No clinical response (persistent fever) after 72hr with appropriate antibiotics - refer to ENT specialist – CT scan, endoscopy or sinus aspiration and cultures may be indicated • Penicillin allergy – if reaction to penicillin only itchy, maculopapular skin rash, use cephalosporin

  14. Rx of ABS +AOM (Adults) Children: amoxycillin 90 mg/kg/d (3 divided doses) x 10 days Adults: amoxycillin 1g 8hrly x 10 days • alternatives: • Amox/clav; Oral cephalosporins; Macrolides; Fluoroquinolones e.g. moxifloxacin • No response to first line drugs: • Amox/clav with high dose amox • Ceftriaxone, IV of IM x 3-5 days if severe infection e.g. peri-orbital inflammation, intra-cranial or extra-sinus complications • Fluoroquinolones

  15. Lower respiratory infection • Acute bronchitis/Acute on chronic bronchitis? • Community-acquired pneumonia • Hospital-acquired pneumonia

  16. Community-acquired Pneumonia (CAP) • Causes: • Streptococcus pneumoniae • Atypical pathogens – Mycoplasma pneumoniae; Chlamydophila pneumoniae; Legionella – cyclic and geographical variation • Respiratory viruses – Influenza A& B • Haemophilus influenzae - COPD • Gram negative Enterobacteria e.g. Klebsiella – elderly; neonate; high morbidity/mortality • Staphylococcus aureus – high morbidity/mortality

  17. Other causes • Polymicrobial – elderly; severe ill patient • Oral anaerobic flora – aspiration (alcoholic; epilepsy; Stroke) • Mycobacterium tuberculosis • HIV +ve pt: • Same as HIV -ve pt • Most common: S. pneumoniae; H. influenzae • Also S. aureus and Gram neg orgs and unusual causes e.g. Pseudomonas aeruginosa and opportunistic pathogens (Pneumocystis) • Pseudomonas • Structural lung disease (cystic fibrosis, bronchiectasis) • Broadspectrum antibiotics in previous month • Recent hospitalisation • Recent Antibiotics exposure in past 3 months: risk for resistance • Do not use same antibiotics; use different class, or in case of beta-lactams a broader spectrum agent

  18. Antibiotic choice/Hospitalisation? • Age (<65yrs versus >65yrs) • Co-morbid disease: • HIV • Chronic heart/lung disease • Renal disease • Liver disease • Diabetes mellitus • Severity of infection – tagipnea, low BP, patient confused?

  19. Empiric antibiotics

  20. alternatives Rx

  21. Addisional Rx • Macrolides (erythromycin; clarithromycin) or • Azalides (azithromycin) or • Tetracyclines (doxycycline) • Not recommended as monotherapy due to high incidence of resistance in S. pneumoniae • As addisional therapy if infection with ‘atypicals’ is suspected or no response on initial Rx

  22. Duration of treatment • Empirical treatment – start as soon as possible, recommend within 4-8hrs of presentation (better outcome) • Optimal duration is uncertain Guidelines: • Elderly; co-morbid disease and HIV pte may require longer Rx • IVoral drugs when good clinical response within 48-72hrs • 5-7 days for typical causes • 14 days for atypicals: Mycoplasma; Chlamydia and Legionella • Give attention to: bed rest, analgesia, nutrition, hydration, oxygenation; support cardiovacular & renal function

  23. Penicillins •  in resistance in S. pneumoniae, due to penicillin-binding protein (PBP) mutations – for resp infections high dose IV treatment will still be effective • H. influenzae – beta-lactamase production may occur conferring resistance to amoxicillin  amox/clav effective • Examples • Penicillin • Ampicillin • Amoxycillin • Amox/clav

  24. Macrolides/Azalides • Increasing resistance in pneumococci • Not appropriate as monotherapy • Agents of choice for atypical pathogens • Examples • erythromycin • clarithromycin • azithromycin (azalide)

  25. Cephalosporins • Oral cephalosporins:cefuroxime (2nd gen); cefpodoxime (3rd gen) • Good activity against staphylococci • IV and PO • 3rd gen. cephalosporins: ceftriaxone; cefotaxime: • Greater Gram negative cover • Due to emerging resistance to cephalosporins in pneumococci high dosages are recommended

  26. Aminoglycosides • Only as part of combination therapy in severely ill patients for Gram negative cover of Enterobacteria e.g. Klebsiella, E.coli. • Can be discontinued if another pathogen is isolated. • Avoid aminoglycosides in the elderly • Gentamycin • Amikacin • Tobramycin

  27. Fluoroquinolones • New agents have better pneumococcal cover • Effective against typical and atypical pathogens • Contra-indications – recent treatment with a fluoroquinolone - due to development of resistance • Moxifloxacin • Levofloxacin

  28. Carbapenems - Ertapenem • Broad spectrum agent • Active against pneumococci; anaerobes; most Enterobacteria (including ESBLs ‘extended spectrum beta-lactamase producers’) • Not active against nonfermenting Gram negative organisms e.g. Pseudomonas, Acinetobacter • Indications: • Elderly with co-morbid illness and/or in longterm care facility or alcoholic • Aspiration pneumonia/suspected anaerobic infection/lung abscess • Cases known or suspected of being infected with resistant pathogens • Failed first line treatment, usually based on microbiological culture results

  29. Tetracyclines • Doxycycline has good activity against H. influenzae, but increasing resistance in pneumococci • Alternative in areas with low resistance or additional therapy against atypical pathogens • Doxycycline

  30. response on therapy • With appropriate therapy a clinical response should occur within 24-72hrs. • Elderly/Co-morbidityresponse slower • if response not optimal, take the following into account: • Is the therapy appropriate? • Is this an unusual pathogen e.g. Pneumocystis? • Does the patient have TB? • Non-infective disease e.g. pulmonary embolus/carcinoma? • Complications e.g. empyema, sepsis?

  31. Hospital-acquired pneumoniaCauses • Post-aspiration e.g. stroke – oral anaerobic flora + S. pneumoniae • Mechanical ventilation – Gram negative Enterobacteria; Pseudomonas aeruginosa

  32. Microbiology of nosocomial pneumonia (NP) • Early or late onset • Severity of infection (ICU or non-ICU) • Risk factors for multi-resistant Gram negative pathogens e.g. Pseudomonas, Acinetobacter, ESBL producing Klebsiella pneumoniae • Recent antibiotics (previous 3mths)/hospitalisation (for period of 5 days)

  33. Microbiology of NP • Early onset NP within 4 days/non-ICU – S. pneumoniae; Haemophilus influenzae, MSSA, Moraxella & antibiotic-S Gram negative bacilli e.g. Klebsiella, E. coli etc. • Late-onset NP/ICU/Ventilation-associated pneumonia (VAP) –same pathogens, but often more resistant e.g. MRSA, multi-resistant Gram negative bacilli e.g. ESBL-producing Klebsiella, also Pseudomonas, Acinetobacter

  34. Hospital acquired pneumoniano empirical regimen covers all causesDo cultures before starting antibiotics!

  35. References • Management of community-acquired pneumonia in adults. SAMJ December 2007, Vol 97, No 12 • Guideline for the Management of Upper Respiratory Tract Infections. SAJEI 2008, Vol. 23, No. 4 Updated Jan 2012

More Related